Display options
Cite
Lim RK, Tremblay A, Lu S, et al. Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study. BMC Pulm Med. 2021;21(1):392doi: 10.1186/s12890-021-01762-6.
Lim, R. K., Tremblay, A., Lu, S., & Somayaji, R. (2021). Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study. BMC pulmonary medicine, 21(1), 392. https://doi.org/10.1186/s12890-021-01762-6
Lim, Rachel K, et al. "Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study." BMC pulmonary medicine vol. 21,1 (2021): 392. doi: https://doi.org/10.1186/s12890-021-01762-6
Lim RK, Tremblay A, Lu S, Somayaji R. Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study. BMC Pulm Med. 2021 Dec 01;21(1):392. doi: 10.1186/s12890-021-01762-6. PMID: 34852812; PMCID: PMC8638373.
Copy Download .nbib Format: NLM
Share it on

BMC Pulm Med. 2021 Dec 01;21(1):392. doi: 10.1186/s12890-021-01762-6.

Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study.

BMC pulmonary medicine

Rachel K Lim, Alain Tremblay, Shengjie Lu, Ranjani Somayaji

Affiliations

  1. Department of Medicine, University of Calgary, Calgary, Canada. [email protected].
  2. Cumming School of Medicine, University of Calgary, Calgary, Canada. [email protected].
  3. Department of Medicine, University of Calgary, Calgary, Canada.
  4. Cumming School of Medicine, University of Calgary, Calgary, Canada.
  5. Department of Microbiology, Immunology and Infectious Disease, University of Calgary, Calgary, Canada.
  6. Department of Community Health Sciences, University of Calgary, Calgary, Canada.

PMID: 34852812 PMCID: PMC8638373 DOI: 10.1186/s12890-021-01762-6

Abstract

BACKGROUND: The burden of hospitalizations and mortality for hemoptysis due to bronchiectasis is not well characterized. The primary outcome of our study was to evaluate in-hospital mortality in patients admitted with hemoptysis and bronchiectasis, as well as the rates of bronchial artery embolization, length of stay, and hospitalization costs.

METHODS: The authors queried the Nationwide Inpatient Sample (NIS) claims database for hospitalizations between 2016 and 2017 using the ICD-10-CM codes for hemoptysis and bronchiectasis in the United States. Multivariable regression was used to evaluate predictors of in-hospital mortality, embolization, length of stay, and hospital costs.

RESULTS: There were 8240 hospitalizations (weighted) for hemoptysis in the United States from 2016 to 2017. The overall in-hospital mortality was 4.5%, but higher in males compared to females. Predictors of in-hospital mortality included undergoing three or more procedures, age, and congestive heart failure. Bronchial artery embolization (BAE) was utilized during 2.1% of hospitalizations and was more frequently used in those with nontuberculous mycobacteria and aspergillus infections, but not pseudomonal infections. The mean length of stay was 6 days and the median hospitalization cost per patient was USD $9,610. Having comorbidities and procedures was significantly associated with increased length of stay and costs.

CONCLUSION: Hemoptysis is a frequent indication for hospitalization among the bronchiectasis population. In-hospital death occurred in approximately 4.5% of hospitalizations. The effectiveness of BAE in treating and preventing recurrent hemoptysis from bronchiectasis needs to be explored.

© 2021. The Author(s).

References

  1. Asian Cardiovasc Thorac Ann. 2017 Nov;25(9):618-622 - PubMed
  2. Open Forum Infect Dis. 2020 May 25;7(6):ofaa173 - PubMed
  3. Chest. 2002 Mar;121(3):796-801 - PubMed
  4. Respiration. 2016;92(1):1-8 - PubMed
  5. Thorax. 2019 Jan;74(Suppl 1):1-69 - PubMed
  6. Asian Cardiovasc Thorac Ann. 2015 Jan;23(1):55-60 - PubMed
  7. Med Sci (Basel). 2017 Sep 23;5(4): - PubMed
  8. Am J Respir Crit Care Med. 2018 Jun 1;197(11):1410-1420 - PubMed
  9. Respir Med. 2006 Dec;100(12):2183-9 - PubMed
  10. Lancet. 2012 Aug 18;380(9842):660-7 - PubMed
  11. Thorax. 2013 Sep;68(9):812-7 - PubMed
  12. Chron Respir Dis. 2017 Nov;14(4):377-384 - PubMed
  13. Lancet Respir Med. 2016 Dec;4(12):969-979 - PubMed
  14. Chest. 2017 May;151(5):982-992 - PubMed
  15. BMC Pulm Med. 2007 Dec 10;7:17 - PubMed
  16. Eur Radiol. 2018 Jul;28(7):2845-2855 - PubMed
  17. Eur Respir J. 2017 Sep 9;50(3): - PubMed
  18. JAMA. 2013 Mar 27;309(12):1260-7 - PubMed
  19. Am J Emerg Med. 2018 Jul;36(7):1160-1165 - PubMed
  20. Respiration. 2000;67(4):412-6 - PubMed
  21. Clin Infect Dis. 2020 Aug 14;71(4):905-913 - PubMed
  22. Infect Dis Ther. 2020 Sep;9(3):511-524 - PubMed
  23. Clin Respir J. 2015 Jan;9(1):53-64 - PubMed
  24. Chest. 2010 Oct;138(4):944-9 - PubMed
  25. JAMA. 2013 Mar 27;309(12):1251-9 - PubMed
  26. BMC Pulm Med. 2019 Jun 27;19(1):117 - PubMed
  27. Chest. 2004 May;125(5):1815-20 - PubMed
  28. BMC Pulm Med. 2019 Feb 28;19(1):54 - PubMed
  29. Am J Respir Crit Care Med. 2013 Sep 15;188(6):647-56 - PubMed
  30. JAMA. 2017 Nov 28;318(20):2011-2018 - PubMed
  31. Diagn Interv Radiol. 2017 Jul-Aug;23(4):307-317 - PubMed
  32. Respir Med. 2010 Jun;104(6):816-21 - PubMed

Publication Types